Difference between revisions of "Part:BBa K200028"
Line 5: Line 5:
 
However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London <i>The E.ncapsulator</i>], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme.
 
However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London <i>The E.ncapsulator</i>], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme.
 
We thus performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine. This change has previously been correlated with resistance against intestinal proteases<cite>#PRPAH1</cite>.
 
We thus performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine. This change has previously been correlated with resistance against intestinal proteases<cite>#PRPAH1</cite>.
 +
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
 
===Usage and Biology===
 
===Usage and Biology===
 
This section is explained in greater detail at the main PAH part page ([https://parts.igem.org/Part:BBa_K200008 BBa_K200008])
 
This section is explained in greater detail at the main PAH part page ([https://parts.igem.org/Part:BBa_K200008 BBa_K200008])
 +
  
 
<!-- -->
 
<!-- -->

Revision as of 23:19, 18 October 2009

Protease resistant PAH

The Homo sapiens endogenous enzyme is synthesised by the liver. However, as part of the Imperial College iGEM 2009 project, [http://2009.igem.org/Team:Imperial_College_London The E.ncapsulator], the enzyme is released in the intestine of the individual. The presence of proteases in the intestine was therefore a serious problem which would jeopardise the viability of the curative enzyme. We thus performed site directed mutagenesis in order to alter a serine residue (Ser16) to a glutamine. This change has previously been correlated with resistance against intestinal proteases#PRPAH1.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 287
    Illegal BamHI site found at 814
    Illegal XhoI site found at 524
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


<biblio>

  1. PRPAH1 pmid=7887915

</biblio>